Gan&Lee doses first participant in GZC8072 Phase 1 study
Gan&Lee Pharmaceuticals announced the first participant has been dosed in a First-In-Human Phase 1 study of GZC8072 tablets, a novel ultra-long-acting once-weekly oral peptide GLP-1 RA.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.